{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T19:53:32Z","timestamp":1773431612409,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,2,4]],"date-time":"2017-02-04T00:00:00Z","timestamp":1486166400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1007\/s00228-017-2205-7","type":"journal-article","created":{"date-parts":[[2017,2,3]],"date-time":"2017-02-03T23:11:41Z","timestamp":1486163501000},"page":"581-591","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["First-in-human studies of seletalisib, an orally bioavailable small-molecule PI3K\u03b4 inhibitor for the treatment of immune and inflammatory diseases"],"prefix":"10.1007","volume":"73","author":[{"given":"Eric","family":"Helmer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Watling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Tytgat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodger","family":"Allen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Payne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annelize","family":"Koch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugene","family":"Healy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,2,4]]},"reference":[{"issue":"4","key":"2205_CR1","doi-asserted-by":"crossref","first-page":"p359","DOI":"10.1111\/1756-185X.12293","volume":"17","author":"LA MacFarlane","year":"2014","unstructured":"MacFarlane LA, Todd DJ (2014) Kinase inhibitors: the next generation of therapies in the treatment of rheumatoid arthritis. Int J Rheum Dis 17(4):p359\u2013p368","journal-title":"Int J Rheum Dis"},{"key":"2205_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2015.10.003","volume":"65","author":"E Zampeli","year":"2015","unstructured":"Zampeli E, Vlachoyiannopoulos PG, Tzioufas AG (2015) Treatment of rheumatoid arthritis: unraveling the conundrum. J Autoimmun 65:1\u201318","journal-title":"J Autoimmun"},{"issue":"5","key":"2205_CR3","doi-asserted-by":"crossref","first-page":"p379","DOI":"10.1007\/s40257-014-0089-1","volume":"15","author":"JD Jensen","year":"2014","unstructured":"Jensen JD, Delcambre MR, Nguyen G, Sami N (2014) Biologic therapy with or without topical treatment in psoriasis: what does the current evidence say? Am J Clin Dermatol 15(5):p379\u2013p385","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"2205_CR4","doi-asserted-by":"crossref","first-page":"p219","DOI":"10.1093\/rheumatology\/keu417","volume":"54","author":"PR Sada","year":"2015","unstructured":"Sada PR, Isenberg D, Ciurtin C (2015) Biologic treatment in Sjogren\u2019s syndrome. Rheumatology (Oxford) 54(2):p219\u2013p230","journal-title":"Rheumatology (Oxford)"},{"key":"2205_CR5","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.coph.2015.05.017","volume":"23","author":"AK Stark","year":"2015","unstructured":"Stark AK, Sriskantharajah S, Hessel EM, Okkenhaug K (2015) PI3K inhibitors in inflammation, autoimmunity and cancer. Curr Opin Pharmacol 23:82\u201391","journal-title":"Curr Opin Pharmacol"},{"key":"2205_CR6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/nyas.12027","volume":"1280","author":"K Okkenhaug","year":"2013","unstructured":"Okkenhaug K (2013) Rules of engagement: distinct functions for the four class I PI3K catalytic isoforms in immunity. Ann N Y Acad Sci 1280:24\u201326","journal-title":"Ann N Y Acad Sci"},{"key":"2205_CR7","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2174\/1874312901206010245","volume":"6","author":"E Banham-Hall","year":"2012","unstructured":"Banham-Hall E, Clatworthy MR, Okkenhaug K (2012) The therapeutic potential for PI3K inhibitors in autoimmune rheumatic diseases. Open Rheumatol J 6:245\u2013258","journal-title":"Open Rheumatol J"},{"issue":"8","key":"2205_CR8","doi-asserted-by":"crossref","first-page":"p2940","DOI":"10.1182\/blood-2007-04-086751","volume":"110","author":"H Ji","year":"2007","unstructured":"Ji H, Rintelen F, Waltzinger C et al (2007) Inactivation of PI3Kgamma and PI3Kdelta distorts T-cell development and causes multiple organ inflammation. Blood 110(8):p2940\u2013p2947","journal-title":"Blood"},{"issue":"2","key":"2205_CR9","doi-asserted-by":"crossref","first-page":"p80","DOI":"10.1016\/j.it.2006.12.007","volume":"28","author":"K Okkenhaug","year":"2007","unstructured":"Okkenhaug K, Ali K, Vanhaesebroeck B (2007) Antigen receptor signalling: a distinctive role for the p110delta isoform of PI3K. Trends Immunol 28(2):p80\u2013p87","journal-title":"Trends Immunol"},{"issue":"4","key":"2205_CR10","doi-asserted-by":"crossref","first-page":"p603","DOI":"10.1016\/j.cellsig.2010.10.002","volume":"23","author":"WP Fung-Leung","year":"2011","unstructured":"Fung-Leung WP (2011) Phosphoinositide 3-kinase delta (PI3Kdelta) in leukocyte signaling and function. Cell Signal 23(4):p603\u2013p608","journal-title":"Cell Signal"},{"issue":"11","key":"2205_CR11","doi-asserted-by":"crossref","first-page":"p2203","DOI":"10.1182\/blood-2009-07-232330","volume":"115","author":"DR Soond","year":"2010","unstructured":"Soond DR, Bjorgo E, Moltu K et al (2010) PI3K p110delta regulates T-cell cytokine production during primary and secondary immune responses in mice and humans. Blood 115(11):p2203\u2013p2213","journal-title":"Blood"},{"issue":"3","key":"2205_CR12","doi-asserted-by":"crossref","first-page":"p552","DOI":"10.1093\/rheumatology\/ker349","volume":"51","author":"VM Bhole","year":"2012","unstructured":"Bhole VM, Choi HK, Burns LC et al (2012) Differences in body mass index among individuals with PsA, psoriasis, RA and the general population. Rheumatology (Oxford) 51(3):p552\u2013p556","journal-title":"Rheumatology (Oxford)"},{"key":"2205_CR13","unstructured":"Food and Drug Administration (FDA) (2002) Guidance for industry. Food-effect bioavailability and fed bioequivalence studies. Series. Guidance for Industry. Food-effect bioavailability and fed bioequivalence studies. http:\/\/www.fda.gov\/downloads\/RegulatoryInformation\/Guidances\/UCM126833.pdf . Accessed: 16 February 2015"},{"issue":"4","key":"2205_CR14","doi-asserted-by":"crossref","first-page":"p2538","DOI":"10.4049\/jimmunol.180.4.2538","volume":"180","author":"K Ali","year":"2008","unstructured":"Ali K, Camps M, Pearce WP et al (2008) Isoform-specific functions of phosphoinositide 3-kinases: p110 delta but not p110 gamma promotes optimal allergic responses in vivo. J Immunol 180(4):p2538\u2013p2544","journal-title":"J Immunol"},{"key":"2205_CR15","unstructured":"UCB data on file: UCB1446368-in vivo-rep; November 2011; UCB BioPharma sprl Belgium and DMPK10_062 UCB1446368 iv 1mpk male HW rat BDC; August 2010; UCB BioPharma sprl Belgium"},{"issue":"5","key":"2205_CR16","doi-asserted-by":"crossref","first-page":"p496","DOI":"10.1056\/NEJMra0804595","volume":"361","author":"FO Nestle","year":"2009","unstructured":"Nestle FO, Kaplan DH, Barker J (2009) Psoriasis. N Engl J Med 361(5):p496\u2013p509","journal-title":"N Engl J Med"},{"issue":"6","key":"2205_CR17","doi-asserted-by":"crossref","first-page":"p676","DOI":"10.1016\/0091-6749(76)90179-2","volume":"58","author":"SR Hirsch","year":"1976","unstructured":"Hirsch SR, Kalbfleisch JH (1976) Circulating basophils in normal subjects and in subjects with hay fever. J Allergy Clin Immunol 58(6):p676\u2013p682","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"2205_CR18","doi-asserted-by":"crossref","first-page":"p1064","DOI":"10.1038\/jid.2008.85","volume":"128","author":"A Blauvelt","year":"2008","unstructured":"Blauvelt A (2008) T-helper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis. J Invest Dermatol. 128(5):p1064\u2013p1067","journal-title":"J Invest Dermatol."},{"issue":"1","key":"2205_CR19","doi-asserted-by":"crossref","first-page":"p79","DOI":"10.1038\/jid.2008.194","volume":"129","author":"LC Zaba","year":"2009","unstructured":"Zaba LC, Fuentes-Duculan J, Eungdamrong NJ et al (2009) Psoriasis is characterized by accumulation of immunostimulatory and Th1\/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol. 129(1):p79\u2013p88","journal-title":"J Invest Dermatol."},{"issue":"1","key":"2205_CR20","doi-asserted-by":"crossref","first-page":"p59","DOI":"10.1111\/bjd.12631","volume":"170","author":"E Christophers","year":"2014","unstructured":"Christophers E, Metzler G, Rocken M (2014) Bimodal immune activation in psoriasis. Br J Dermatol 170(1):p59\u2013p65","journal-title":"Br J Dermatol"},{"issue":"10","key":"2205_CR21","doi-asserted-by":"crossref","first-page":"p691","DOI":"10.1007\/s00403-011-1169-1","volume":"303","author":"CM Sweeney","year":"2011","unstructured":"Sweeney CM, Tobin AM, Kirby B (2011) Innate immunity in the pathogenesis of psoriasis. Arch Dermatol Res 303(10):p691\u2013p705","journal-title":"Arch Dermatol Res"},{"issue":"1","key":"2205_CR22","doi-asserted-by":"crossref","first-page":"p268","DOI":"10.1038\/jid.2013.289","volume":"134","author":"FL Shaw","year":"2014","unstructured":"Shaw FL, Mellody KT, Ogden S, Dearman RJ, Kimber I, Griffiths CE (2014) Treatment-related restoration of Langerhans cell migration in psoriasis. J Invest Dermatol. 134(1):p268\u2013p271","journal-title":"J Invest Dermatol."},{"key":"2205_CR23","doi-asserted-by":"crossref","unstructured":"C. L. Lucas, A. Chandra, S. Nejentsev, A. M. Condliffe and K. Okkenhaug (2016) PI3K[delta] and primary immunodeficiencies. Nat Rev Immunol. advance online publication","DOI":"10.1038\/nri.2016.93"},{"issue":"3\u20134","key":"2205_CR24","doi-asserted-by":"crossref","first-page":"p278","DOI":"10.1016\/j.jaut.2011.02.006","volume":"36","author":"S Haylock-Jacobs","year":"2011","unstructured":"Haylock-Jacobs S, Comerford I, Bunting M et al (2011) PI3Kdelta drives the pathogenesis of experimental autoimmune encephalomyelitis by inhibiting effector T cell apoptosis and promoting Th17 differentiation. J Autoimmun 36(3\u20134):p278\u2013p287","journal-title":"J Autoimmun"},{"key":"2205_CR25","first-page":"256","volume":"3","author":"KD Puri","year":"2012","unstructured":"Puri KD, Gold MR (2012) Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies. Front Immunol 3:256","journal-title":"Front Immunol"},{"issue":"9","key":"2205_CR26","doi-asserted-by":"crossref","first-page":"p4612","DOI":"10.4049\/jimmunol.1103173","volume":"189","author":"A Roller","year":"2012","unstructured":"Roller A, Perino A, Dapavo P et al (2012) Blockade of phosphatidylinositol 3-kinase PI3Kdelta or PI3Kgamma reduces IL-17 and ameliorates imiquimod-induced psoriasis-like dermatitis. J Immunol 189(9):p4612\u2013p4620","journal-title":"J Immunol"},{"key":"2205_CR27","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1038\/cddis.2012.69","volume":"3","author":"S Madonna","year":"2012","unstructured":"Madonna S, Scarponi C, Pallotta S, Cavani A, Albanesi C (2012) Anti-apoptotic effects of suppressor of cytokine signaling 3 and 1 in psoriasis. Cell Death Dis 3:e334","journal-title":"Cell Death Dis"},{"issue":"10","key":"2205_CR28","doi-asserted-by":"crossref","first-page":"p2445","DOI":"10.1038\/sj.jid.5700874","volume":"127","author":"C Rosenberger","year":"2007","unstructured":"Rosenberger C, Solovan C, Rosenberger AD et al (2007) Upregulation of hypoxia-inducible factors in normal and psoriatic skin. J Invest Dermatol 127(10):p2445\u2013p2452","journal-title":"J Invest Dermatol"},{"key":"2205_CR29","unstructured":"Infinity Pharmaceuticals (2015) Press release: Infinity reports topline results from Phase 2 study of duvelisib in rheumatoid arthritis."}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-017-2205-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-017-2205-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-017-2205-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T14:59:54Z","timestamp":1589727594000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-017-2205-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,4]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["2205"],"URL":"https:\/\/doi.org\/10.1007\/s00228-017-2205-7","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,4]]}}}